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A strong interplay exists between pop-
ulation health and economic growth (1). 
First, high-income populations tend to 
have better health because they have ac-
cess to more and better nutrition; safe 
water and sanitation; readily available 
ABSTRACT Objective. We extend the EPIC model of the World Health Organization (WHO) and apply 
it to analyze the macroeconomic impact of noncommunicable diseases (NCDs) and mental 
health conditions in Costa Rica, Jamaica, and Peru.
Methods. The EPIC model quantifies the impact of NCDs and mental health conditions on 
aggregate output solely through the effect of chronic conditions on labor supply due to mortal-
ity. In contrast, the expanded EPIC-H Plus framework also incorporates reductions in effective 
labor supply due to morbidity and negative effects of health expenditure on output via the 
diversion of productive savings and reduced capital accumulation. We apply this methodology 
to Costa Rica, Jamaica, and Peru and estimate gross domestic product (GDP) output lost due 
to four leading NCDs (cardiovascular disease, cancer, chronic respiratory disease, and diabetes) 
and mental health conditions in these countries from 2015 to 2030. We also estimate losses 
from all NCDs and mental health conditions combined.
Results. Overall, our results show total losses associated with all NCDs and mental health 
conditions over the period 2015–2030 of US$ 81.96 billion (2015 US$) for Costa Rica, 
US$ 18.45 billion for Jamaica, and US$ 477.33 billion for Peru. Moderate variation exists in 
the magnitude of the burdens of diseases for the three countries. In Costa Rica and Peru, respi-
ratory disease and mental health conditions are two leading contributors to lost output, while 
in Jamaica, cardiovascular disease alone accounts for 20.8% of the total loss, followed by cancer.
Conclusions. These results indicate that the economic impact of NCDs and mental health 
conditions is substantial and that interventions to reduce the prevalence of chronic conditions 
in countries of Latin America and the Caribbean are likely to be highly cost-beneficial.
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West Indies.
1 Department of Global Health and Population, 
Harvard T.H. Chan School of Public Health, 
Boston, Massachusetts, United States of America. 
Send correspondence to David E. Bloom at 
dbloom@hsph.harvard.edu
2 CHaRMS – Centre for Health Research at Queen’s 
Management School, Queen’s University Belfast, 
Belfast, Antrim, Northern Ireland.
and quality health care; and psychoso-
cial resources, such as social capital and 
recreation facilities. Second, healthy 
populations develop faster economically 
because healthy work forces tend to be 
more productive and because healthy 
children have higher test scores, better 
school attendance records, and higher 
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levels of educational attainment. In ad-
dition, healthy populations maintain 
higher rates of saving, investment, and 
physical capital accumulation because 
they expend fewer resources on health 
care. This process may lead to a virtuous 
cycle that results in further investment 
from abroad, increasing workers’ access 
to more-productive machines, technol-
ogy, and infrastructure. Healthy popula-
tions also tend to control their fertility, 
allowing them to escape the burden of 
youth dependency and enjoy a demo-
graphic dividend (2). Therefore, under-
standing patterns in population health 
is likely to be important, at least in part, 
for understanding patterns in economic 
growth.
Noncommunicable diseases (NCDs) 
and mental health conditions represent a 
huge disease burden and have a substan-
tial impact on individuals, communities, 
and societies around the globe. In total, 
these conditions are responsible for 
roughly half of healthy life years lost as 
measured in disability-adjusted life years 
(DALYs) and roughly two-thirds of 
deaths worldwide (3, 4). In the Region of 
the Americas, NCDs are the leading 
cause of morbidity and mortality and are 
responsible for 80% of all deaths (5). Of 
particular relevance, 35% of NCD-re-
lated deaths occur prematurely (between 
the ages of 30 and 70), when individuals 
are in their most economically produc-
tive period of life (5).
As worrying as current rates of NCDs 
and mental health conditions are, trends 
in the relevant risk factors for these con-
ditions indicate that their global burden 
is only likely to grow. For example, while 
smoking has declined in some high-in-
come countries, the overall rates of the 
main modifiable risk factors for NCDs 
and mental health conditions—such as 
tobacco use, alcohol use, and obesity—
have risen globally, suggesting that an 
increase in the rates of chronic conditions 
worldwide is likely to follow (6, 7). In ad-
dition, more sedentary occupations and 
unhealthy diets are becoming more 
common.
Demographic trends also point toward 
an increased future burden from NCDs 
and mental health conditions. In particu-
lar, the dual phenomena of urbanization 
and rapid population aging have signifi-
cant implications. Although urbaniza-
tion has many benefits in terms of 
efficiency and convenience, it can also 
facilitate dispersion of certain risk factors 
for NCDs, such as pollution and sec-
ond-hand smoking. Given that age con-
stitutes the main risk factor for NCDs 
and mental health conditions, global 
population aging is likely to have a ma-
jor effect on overall levels of population 
health. While a thorough discussion of 
the prevalence of these conditions is be-
yond the scope of this paper, these de-
tails have been provided elsewhere. In 
addition, more information on NCDs in 
the Americas and the capacity of coun-
tries to respond is available in a report 
that was prepared by the Pan American 
Health Organization (PAHO) (8).
In spite of the high burden of ill health 
and premature death caused by NCDs 
and mental conditions, the availability of 
data capturing their economic impact is 
limited (9). This paper focuses on Costa 
Rica, Jamaica, and Peru (see Table 1 for 
summary statistics) and is the result of a 
collaboration between the Harvard T.H. 
Chan School of Public Health and the 
PAHO Department of Noncommunica-
ble Diseases and Mental Health. That 
department is responsible for providing 
technical cooperation in the Region of 
the Americas to prevent and control 
NCDs, as well as mental conditions, and 
related risk factors in accordance with 
global and regional mandates (10).
This paper has two goals. The first is to 
estimate the economic impact of NCDs 
and mental conditions on gross domestic 
product (GDP). The second is to raise 
awareness among policymakers and 
other decisionmakers of these condi-
tions’ economic costs and their implica-
tions for national economic progress. 
Finance ministers and others in charge of 
resource allocation are more likely to 
fund programs and interventions that 
are evidence based, and persons seeking 
to influence financial decisions (such as 
by health ministers) can use the results 
presented in this paper to identify and 
promote the adoption of cost-effective 
policies, such as the “best buy” NCD 
interventions identified by the World 
Health Organization (WHO) (11, 12).
Although Costa Rica, Jamaica, and 
Peru represent different geographic ar-
eas in Latin America and the Caribbean 
and have different levels of economic 
development, they face similar demo-
graphic challenges, including recent 
steady increases in the proportions of 
their populations aged 60 and above 
(Figure 1). In 1980, the proportion of the 
population aged 60 and above was 9.3% 
for Jamaica, 6.1% for Costa Rica, and 
5.6% for Peru. This age group now ac-
counts for 13% of the Jamaican and 
Costa Rican populations and 10% of the 
Peruvian population. According to 
United Nations Population Division 
(UNPD) projections (https://esa. un.
org/unpd/wpp/Download/Standard/
Population/), by 2050, those aged 60 
and above will account for 30% of the 
population in Costa Rica, 28% in Ja-
maica, and 23% in Peru.
Even though NCDs and mental health 
conditions have a significant and grow-
ing impact on the health and well-being 
of populations, policymakers and the 
public may not be aware of their full con-
sequences. Public spending on large- 
scale intervention programs aimed at 
reducing the risk factors for these dis-
eases (such as obesity) may therefore 
need to be justified by comparing the ex-
pected return on investment from these 
programs with expected returns from 
other potential uses of public funds. This 
can only be achieved if robust estimates 
of the economic costs of NCDs and men-
tal health conditions are available.
Unfortunately, assessing the economic 
impact of NCDs and mental health con-
ditions is complex. Several approaches 
to evaluating the economic effects of 
chronic conditions exist, including cost-
of-illness and value-of-a-statistical-life 
(VSL) methods, which aggregate esti-
mates from individual data. The cost-of-
illness method sums up direct medical 
TABLE 1. Summary statistics for Costa Rica, Jamaica, and Peru
Statistic Costa Rica Jamaica Peru
Population (millions, 2014) 4.8 2.7 31
2014 gross domestic product (billions, 2005 constant US$) 29.4 11.2 127.7
2014 gross domestic product per capita (2005 constant US$) 6 188 4 112 4 124
Savings rate (%)a 17 15 21
Life expectancy (years, 2013) 79.2 73.4 74.3
Percentage of persons 60+ (2015) 12.8 12.8 10.0
Source: Data from the World Bank (http://data.worldbank.org/).
a The savings rate is the average rate between 2011 and 2014.
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costs, while VSL infers the monetary 
value of mortality reductions from will-
ingness-to-pay studies or wage premia 
for risky occupations. However, these 
approaches do not capture the ways in 
which society’s health status affects de-
terminants of economic growth, such as 
labor markets and capital accumulation.
We expect such macro-level spillover 
effects to be important—a hypothesis 
that the literature supports (13). For ex-
ample, NCDs and mental health condi-
tions increase mortality and reduce 
productivity, thus reducing labor supply 
(14). Likewise, health care expenditures 
increase in response to chronic condi-
tions, diverting savings away from pro-
ductive investments and thus reducing 
capital accumulation.
One approach to estimating the impact 
of these spillover effects uses cross-coun-
try economic growth regressions (15, 16); 
however, identifying the parameters of 
interest can be difficult. An alternative is 
to build a working model of the econ-
omy, which can then be calibrated using 
observed data on chronic conditions and 
other country-specific characteristics. We 
can use such production function ap-
proaches to simulate different scenarios 
with different prevalence levels of NCDs 
and mental health conditions. Compar-
ing levels of GDP and of GDP growth in 
various scenarios provides an economic 
estimate of the impact of these health 
conditions.
It should be acknowledged that this 
methodology also has limitations. For ex-
ample, we do not consider the behavioral 
change of individuals and firms. One po-
tential alternative is to use a general equi-
librium approach. However, building 
such a model would be complex and 
could ultimately require too many restric-
tive assumptions to be tractable.
Despite these limitations, our method-
ology has two distinct benefits. First, it is 
an economically founded approach to 
estimating the cost of chronic conditions 
that captures the aggregate impact on so-
ciety rather than on individuals. Second, 
it enables us to describe how the labor 
market and capital stock—key determi-
nants of economic growth—respond to 
NCDs and mental health conditions and 
therefore incorporate adjustment mecha-
nisms. In this paper, we describe how we 
apply this production function approach 
to Costa Rica, Jamaica, and Peru.
METHODS
We analyzed the economic burden 
of NCDs and mental health conditions 
using the EPIC-H Plus model. EPIC-H 
Plus is an updated version of two mod-
els: 1) the original WHO EPIC model 
and 2) our previous EPIC-H model (17). 
The original WHO EPIC model estimates 
the impact of NCDs and mental health 
conditions on aggregate output by quan-
tifying reductions in the labor supply 
due to mortality from chronic conditions. 
As in the original WHO EPIC model, 
GDP is modeled as a function of aggre-
gate labor supply, the aggregate capital 
stock, and technological progress. Health 
is incorporated into this framework be-
cause chronic conditions, including 
NCDs and mental health conditions, af-
fect the quantity of  labor supplied in the 
model. A higher prevalence of NCDs and 
mental health conditions reduces GDP 
because the number of working-age indi-
viduals, and therefore the size of the la-
bor force, decreases.
For accuracy of predictions, modeling 
and coding adjustments were made to 
the original WHO EPIC model to produce 
an updated model, which we refer to as 
EPIC-H. We subsequently developed and 
amended this model to produce the aug-
mented EPIC-H Plus extension, which 
additionally incorporates labor supply 
reductions due to morbidity and the neg-
ative effects of health expenditures on 
output, which result from the diversion of 
productive savings and from reduced 
capital accumulation. (See Appendix B for 
a detailed description of data sources for 
the parameters used in this framework.)
The projections for national income in 
this framework are based on the Solow 
model production function, which is 
given by
 = a −a1Y A K Lt t t t  (1)
where economic output in each year (Yt) 
is modeled as a function of technological 
progress (At), the capital stock (Kt), and 
the stock of labor in the economy (Lt). Al-
pha (a) describes how labor and capital 
combine to produce output. The produc-
tion function is calibrated based on data 
obtained for each country, which include 
forecasts of population structure and the 
prevalence of NCDs and mental health 
conditions. To obtain the aggregate cost 
of NCDs and mental health conditions, 
we simulate aggregate income for each 
country over the period of interest in two 
scenarios: status quo and counterfactual.
Status quo scenario
GDP gives economic output in each 
year as forecasted, assuming the prev-
alence of NCDs and mental health 
FIGURE 1. Percent of total population aged 60+ in Costa Rica, Jamaica, Peru, Latin 
America and the Caribbean, and the world, in 1980, 2015, and 2050
Source: Data from the United Nations Population Division.
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conditions evolves as expected over the 
period of interest. We assume that no 
 interventions that would reduce the 
mortality rate of a disease have been 
implemented.
Counterfactual scenario
This scenario models the complete elim-
ination of the specified disease (i.e., the 
prevalence of NCDs and mental health 
conditions is set to zero), and this reduc-
tion in disease prevalence occurs without 
cost. When considered alongside the sta-
tus quo scenario, the counterfactual sce-
nario can be used to calculate the total 
output loss attributable to NCDs and 
mental health conditions, and this will be 
the focus of this article’s analysis.
The model can also be extended to ex-
amine a proposed intervention scenario. 
In such an intervention scenario, GDP is 
calculated assuming the elimination of a 
designated percentage of mortality for 
the specified disease. For example, this 
could be used to evaluate an intervention 
that reduces the prevalence of NCDs and 
mental health conditions by 10%. In this 
piece, we do not consider an intervention 
scenario as part of the analysis as we fo-
cus on estimating the aggregate cost of 
NCDs and mental health conditions.
After constructing the GDP projections 
for these two scenarios, the difference be-
tween GDP values in the counterfactual 
scenario and in the status quo scenario 
gives the aggregate cost of NCDs and 
mental health conditions. The sum of 
these differences in each year over the 
period of interest gives the total burden. 
Appendix A has a detailed description of 
the modeling methodology. Further de-
tails of model functionality and deriva-
tions are given in Bloom et al. (17, 18).
RESULTS
Tables A2, A3, and A4 (see Appendix 
C) present baseline-case estimates of the 
economic burden of NCDs and mental 
health conditions for Costa Rica, Jamaica, 
and Peru, during the period of 2015 to 
2030. The estimates, which are given in 
2015 US$, draw on WHO mortality data 
and assume that the same mortality rates 
observed from 2005 through 2013 will 
hold for 2015-2030. In addition to sepa-
rate economic burden estimates for each 
of four leading noncommunicable dis-
eases (diabetes, cardiovascular disease 
(CVD), chronic respiratory disease, and 
cancer) and mental health conditions, es-
timates of the aggregate cost of all NCDs 
and mental health conditions are pre-
sented in each table. These aggregate es-
timates were obtained by scaling the 
figure for the five domains using the pro-
cedure based on disability-adjusted life 
years (DALYs) that is described by Bloom 
et al. (17, 18).
The costs associated with NCDs 
and mental health conditions in 
the three countries are substantial
According to the model, all NCDs 
and mental health conditions will cost 
Costa Rica, Jamaica, and Peru, respec-
tively, US$ 81.96 billion (US$ 16 143 
per capita), US$ 18.45 billion (US$ 6 306 
per capita), and US$ 477.33 billion 
(US$ 15 010 per capita), in 2015 US$, 
from 2015 through 2030. Considering 
these countries’ income per capita and 
the size of their economies, these figures 
represent huge costs. For Costa Rica, Ja-
maica, and Peru, estimates of the value 
of lost output are, respectively, 142%, 
105%, and 255% of the countries’ 2013 
GDP. Furthermore, these estimates 
amount to more than 48 times Peru’s to-
tal health spending in 2013, and more 
than 18 and 15 times that of Jamaica and 
Costa Rica, respectively.
Moderate variation exists in the 
magnitude of the burdens of 
diseases for the three countries
In Costa Rica, respiratory disease 
alone accounts for 20.1% of the total 
loss, followed by mental health condi-
tions (18.6%), and cardiovascular disease 
(9.4%); diabetes accounts for only 6%. 
Peru faces a similar situation: respiratory 
disease (19.7%), mental health condi-
tions (20.9%), and cardiovascular disease 
(8.4%) are the three leading contributors 
to lost output, while diabetes accounts 
for only 4.2%. In Jamaica, the magnitude 
of the burden associated with specific 
diseases varies somewhat less than in 
the other two countries: CVD contributes 
20.8% to the total loss, followed by can-
cer (13.7%) and diabetes (13.5%).
The burden of NCDs and mental 
health conditions in Peru is greater 
than the burden in Costa Rica and 
Jamaica
Figures 2, 3, and 4 compare the output 
losses due to NCDs and mental health 
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FIGURE 2. Estimates of lost gross domestic product (GDP) output due to four leading 
noncommunicable diseases (NCDs), mental health conditions, and all NCDs and 
mental health conditions in Costa Rica, Jamaica, and Peru, 2015–2030
Source: Prepared by the authors based on the results of the study.
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conditions in Costa Rica, Jamaica, and 
Peru. We present the output losses due to 
four leading noncommunicable diseases 
(cardiovascular disease, cancer, chronic 
respiratory disease, and diabetes), men-
tal health conditions, and total NCDs. 
Here, total NCDs (all NCDs plus mental 
health conditions) include cardiovascu-
lar diseases, cancer, chronic respiratory 
diseases, cirrhosis, digestive diseases, 
 diabetes, urogenital diseases, blood dis-
eases, endocrine diseases, musculoskele-
tal disorders and other noncommunicable 
diseases (including congenital anoma-
lies, skin and subcutaneous diseases, 
sense organ diseases, and oral disorders), 
and mental health conditions. Between 
2015 and 2030, Peru will suffer a larger 
total output loss than either Costa Rica or 
Jamaica (US$ 477.33 billion versus US$ 
81.96 billion and US$ 18.45 billion, re-
spectively). This higher aggregate output 
loss may be due to Peru’s larger popula-
tion and initially higher level of eco-
nomic output. Peru has 6 times the 
population of Costa Rica and almost 11 
times that of Jamaica, with 4 times the 
GDP of Costa Rica and almost 10 times 
that of Jamaica.
Peru not only has the highest output 
loss among the countries studied at the 
aggregate level, but also the largest at the 
per capita level (US$ 16 143). Further-
more, Peru’s burden of NCDs and men-
tal health conditions is much larger when 
compared with its baseline GDP. In 2015–
2030, total losses related to NCDs and 
mental health conditions for Costa Rica 
and Jamaica, respectively, are estimated 
at 142% and 105% of the countries’ 2013 
GDPs, while the corresponding loss for 
Peru over the same time period is 255% 
of its 2013 GDP. NCDs and mental health 
conditions therefore pose a larger burden 
for Peru’s economy in both absolute and 
relative terms. Among chronic condi-
tions, respiratory diseases and mental 
health conditions are the leading causes 
of lost output in Peru.
The lower per capita loss in Jamaica 
does not necessarily mean that the bur-
den of NCDs is small. It is mostly a result 
of the low GDP per capita in Jamaica 
at the beginning of the projection period. 
In addition, Jamaica’s GDP is expected 
to grow more slowly than that of Peru 
and of Costa Rica (according to economic 
data from the World Bank); as a result, 
the expected per capita loss will be 
smaller.
We also conducted sensitivity analyses 
by varying data sources and assump-
tions (Appendix D). As it is not possible 
to validate our estimates directly, it is im-
portant to provide evidence that our re-
sults are robust to a variety of mortality 
scenarios. From the sensitivity analysis, 
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we conclude that the results are similar 
and robust across different projection 
methods and data sources, and that the 
impact of treatment cost and morbidity 
is quite significant.
DISCUSSION
Our study has several implications. 
The first is that substantial costs are asso-
ciated with NCDs and mental health con-
ditions in these three countries of Latin 
America and the Caribbean. Unless the 
prevalence of chronic conditions can be 
reduced, the impact on economic growth 
is likely to be substantial, due to conse-
quent reductions in effective labor supply 
and capital accumulation. Correspond-
ingly, the estimates imply that cost-effec-
tive interventions targeted at reducing 
the prevalence of chronic conditions 
are likely to be cost-beneficial because of 
the substantial economic  burden that 
NCDs and mental health conditions im-
pose. Furthermore, implementing inter-
ventions designed to reduce risk factors 
for NCDs is likely to lead to a 25% reduc-
tion in premature mortality from NCDs 
by 2025 (a goal set forth by the WHO 
Global Action Plan for the Prevention 
and Control of Noncommunicable Dis-
eases 2013–2020 (10)). Finally, these inter-
ventions could serve as a strategy to 
promote economic development, given 
the expected impact on labor supply and 
capital accumulation, and therefore on 
economic activity and output.
Caveats
The results we present here are based 
on a set of assumptions about how econ-
omies grow and how various inputs, in-
cluding health, affect economic output. 
We assume that there is no excess labor 
available to replace the labor (or rather, 
effective labor) lost due to NCD-related 
mortality or morbidity. This assumption 
may be less valid in countries in which 
unemployment is high or in which there 
are large shadow economies. However, 
it is difficult to assess the magnitude of 
these effects on real output (as opposed 
to measured GDP). These assumptions 
should be borne in mind when interpret-
ing the estimates, and this is an impor-
tant topic for future research.
Our results are also based on data that 
were available and accessible at the time 
of writing. We have attempted to assess 
the sensitivity of these estimates to dif-
ferent information sources and assump-
tions; however, in pursuing this analysis, 
we found the dearth of quality data to be 
a major impediment to estimating the 
economic impact of NCDs and mental 
health conditions. Estimates using alter-
native mortality sources were found to 
differ, albeit not substantially in most 
cases. More importantly, obtaining com-
prehensive information on the treatment 
costs associated with each disease was 
difficult. For example, due to a lack of 
country-specific data, we were forced to 
rely on several different sources to esti-
mate treatment costs for Costa Rica. By 
contrast, the availability of country-spe-
cific treatment cost data for Jamaica and 
Peru allowed us to provide estimates 
for these countries that are likely more 
accurate.
As another example of a data limita-
tion, we determined that we should 
use DALY estimates to approximate the 
 morbidity impact of different conditions. 
Alternative ways of quantifying this im-
pact rely on survey data and have the 
merit of providing a direct measure of 
the effect of morbidity (e.g., the associa-
tion between having a condition and 
hours worked). However, these alterna-
tive methods may require strong as-
sumptions about how costs are measured 
(e.g., that the relationship is causal).
Moving forward, we recommend that 
evaluations of the impact of NCDs 
and mental health conditions begin by 
 encouraging the collection of compre-
hensive data to better measure the path-
ways linking NCDs and mental health 
conditions to economic outcomes. For 
example, expenditure surveys based on 
nationally representative samples of 
 patients in each country could help to de-
termine the actual costs associated with 
each disease of interest. Then, these esti-
mates would not have to be inferred ei-
ther indirectly from other sources or from 
cost data in other countries, as is cur-
rently necessary. Finally, although we fo-
cus on projecting future scenarios in this 
paper, it would be interesting to evaluate 
the historical impact of NCDs on eco-
nomic growth in a different analysis.
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RESUMEN Objetivo. Ampliamos el modelo EPIC de la Organización Mundial de la Salud 
y lo aplicamos para analizar el impacto macroeconómico de las enfermedades no 
transmisibles y la enfermedad mental en Costa Rica, Jamaica y Perú.
Métodos. El modelo EPIC cuantifica el impacto de las enfermedades no transmisibles 
y la enfermedad mental en la producción agregada únicamente a través del efecto que 
las enfermedades crónicas producen sobre la oferta de trabajo debido a la mortalidad 
que estas causan. En cambio, el marco ampliado EPIC-H Plus también incorpora 
reducciones en la oferta efectiva de trabajo debido a la morbilidad y los efectos nega-
tivos del gasto en salud sobre la producción a través del desvío del ahorro productivo 
y la reducción de la acumulación de capital. Aplicamos esta metodología a Costa 
Rica, Jamaica y Perú y estimamos la pérdida en términos de producto interno bruto 
debida a cuatro enfermedades no transmisibles (enfermedades cardiovasculares, 
cáncer, enfermedad respiratoria crónica y diabetes) y a la enfermedad mental en estos 
países desde 2015 a 2030. También estimamos las pérdidas de todas las enfermedades 
no transmisibles y la enfermedad mental combinadas.
Resultados. En general, nuestros resultados muestran pérdidas totales asociadas con 
todas las enfermedades no transmisibles y la enfermedad mental durante el período 
2015–2030 de USD 81,96 mil millones (en dólares de 2015) para Costa Rica, USD 18,45 mil 
millones para Jamaica y USD 477,33 mil millones para Perú. Existe una variación mode-
rada en la magnitud de la carga de las enfermedades para los tres países. En Costa Rica 
y Perú, las afecciones respiratorias y la enfermedad mental son los dos factores princi-
pales que contribuyen a la pérdida de producción, mientras que en Jamaica la enferme-
dad cardiovascular sola representa el 20,8% de la pérdida total, seguida por el cáncer.
Conclusiones. Estos resultados indican que el impacto económico de las enfermeda-
des no transmisibles y la enfermedad mental es considerable y que las intervenciones 
para reducir la prevalencia de enfermedades crónicas en América Latina y el Caribe 
probablemente sean muy beneficiosas en relación al costo.
Palabras clave Enfermedad crónica; salud mental; economía; envejecimiento; costo de enfermedad; 
América Latina; Indias Occidentales.
La carga económica de 
las enfermedades no 
transmisibles y la 
enfermedad mental: 
resultados para Costa 
Rica, Jamaica y Perú
RESUMO Objetivo. Estendemos o modelo EPIC da Organização Mundial da Saúde e aplicamos 
para analisar o impacto macroeconômico das doenças não transmissíveis (DNT) e as 
condições de saúde mental na Costa Rica, Jamaica e Peru.
Métodos. O modelo EPIC quantifica o impacto das DNT e condições de saúde mental 
na produção agregada unicamente através do efeito de condições crônicas na oferta de 
trabalho devido à mortalidade. Em contrapartida, a estrutura ampliada EPIC-H Plus 
também incorpora reduções na oferta de trabalho efetiva devido à morbidade e aos 
efeitos negativos das despesas de saúde na produção através do desvio de poupanças 
produtivas e redução da acumulação de capital. Aplicamos essa metodologia à Costa 
Rica, Jamaica e Peru e estimamos a perda de produto interno bruto devido a quatro 
DNT (doenças cardiovasculares, câncer, doenças respiratórias crônicas e diabetes) 
e condições de saúde mental nesses países de 2015 a 2030. Também estimamos as 
perdas de todas as DNT e condições de saúde mental combinadas.
Resultados. No geral, nossos resultados mostram perdas totais associadas a todas as 
DNT e condições de saúde mental no período 2015–2030 de USD 81,96 bilhões (USD de 
2015) para a Costa Rica, USD 18,45 bilhões para a Jamaica e USD 477,33 bilhões para o 
Peru. Existe variação moderada na magnitude da carga das doenças para os três países. 
Na Costa Rica e no Peru, as doenças respiratórias e as condições de saúde mental são 
dois principais contribuintes para a perda de produção, enquanto na Jamaica, a doença 
cardiovascular sozinha representa 20,8% da perda total, seguida de câncer.
Conclusões. Esses resultados indicam que o impacto econômico das doenças não 
transmissíveis e as condições de saúde mental são substanciais e que as intervenções 
para reduzir a prevalência de condições crônicas em países da América Latina e do 
Caribe são benéficos em relação ao custo.
Palavras-chave Doença crônica; saúde mental; economia; envelhecimento; efeitos psicossociais da 
doença; América Latina; Índias Ocidentais.
A carga econômica das 
doenças não transmissíveis 
e condições de saúde 
mental: resultados para a 
Costa Rica, Jamaica e Peru
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APPENDIX A. Mathematical formulation 
Modeling the mortality and morbidity impact of NCDs and mental health conditions on labor 
supply 
In our model, age-specific disease mortality and morbidity affect labor supply. The impact of 
mortality is straightforward: it directly reduces the size of the working-age population. However, the 
impact of morbidity is more complicated: it can lower labor supply through early retirement, reduced 
productivity, and reduced working hours. The effect of morbidity is theoretically substantial but because 
of a lack of data and the difficulties associated with determining causality from survey-based information, 
it is hard to quantify in practice.  
There are very few, if any, systematic studies that provide a comprehensive assessment of the 
disability impact of having a given condition on labor market productivity. Therefore, we cannot calibrate 
this effect directly from the literature. There are two alternative approaches we could adopt: first, estimate 
the productivity effect ourselves using survey data; second, model the productivity effect with certain 
assumptions. For the former, we require estimates of the causal effect of having a given health condition 
(e.g., diabetes) on, say, working hours. The causal effect is required because simple associations could 
either under- or overestimate the economic impact of interest. Conducting survey analysis for multiple 
conditions, let alone in multiple countries, would be a major undertaking that is beyond the scope of this 
paper. In this paper, we therefore adopted the latter approach. More specifically, we assume the following 
relationship holds: 
loss of labor due to morbidity
loss of labor due to mortality
=
YLD
YLL
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where YLD is years lost due to living with disability and YLL is years of life lost due to mortality. The 
sum of YLD and YLL make up the total DALYs associated with a given condition, which is widely used 
as a measure of disease burden, according to Lim et al. (19). We assume that the loss of effective labor 
supply due to morbidity can be derived from the proportion of total DALYs (DALYs = YLD + YLL) due 
to years lived with a disability (YLD). In other words, we assume that the ratio of effective labor lost due 
to morbidity relative to labor lost due to mortality is proportional to the ratio of YLD relative to YLL. If 
this assumption holds, we can weight the value of effective labor lost due to mortality (which we can 
estimate) by the contribution of YLL to total DALYs lost to obtain the sum of the value of labor lost to 
mortality and labor lost to morbidity. For example, if YLD constitute 50% of DALYs lost due to cancer, 
and our estimate of the value of labor lost due to cancer mortality is US$ 10 billion, then our weighted 
estimate of the value of labor lost due to cancer morbidity and mortality combined is: 
1
50%
∗ US$ 10 billion = US$ 20 billion.  
This assumption that the contribution of mortality and morbidity to total economic costs occurs in 
the same proportion as the contribution of mortality and morbidity to the total health impact (as measured 
by DALYs) has its limitations. However, we believe it represents a good first step at attempting to 
estimate the approximate magnitude of the quantity of interest, especially considering the limitations of 
alternative approaches to quantify the morbidity impact. As an example of how this assumption impacts 
the future supply of labor, the mortality associated with diabetes in the year 2030 would reduce the 
effective labor supply in Peru by 0.46%, while the morbidity associated with diabetes would further 
reduce effective labor by another 0.27%. 
Real data and official projections provide the labor supply in the status quo scenario. Simulating 
the evolution of labor supply over time after eliminating the mortality and morbidity effects of NCDs and 
mental health conditions provides the labor supply in the counterfactual scenario.  
Modeling the impact of NCDS and mental health conditions on physical capital 
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Health expenditure aimed at treating NCDs and mental health conditions diverts savings away 
from productive investments that are otherwise assumed to create physical capital. The impact of NCDs 
and mental health conditions on physical capital is therefore modeled explicitly through the relevant 
accumulation process:  
1) For the status quo scenario, the accumulation of physical capital simply follows the usual Solow form:  
Kt+1 = sYt + (1 − δ)Kt                                               (2) 
2) For the counterfactual and intervention scenarios, the treatment and intervention costs modify the 
accumulation of physical capital: 
Kt+1 = sYt + (1 − δ)Kt + χTCt                                   (3) 
where s is the savings rate, δ is the depreciation rate of physical capital, χ is the proportion of savings that 
goes to either treatment or intervention costs, and TCt is treatment cost. Specifically, TCt refers to the 
costs of undergoing treatment (or, potentially, alternative prevention strategies). Note that in the 
counterfactual scenario, where diseases are eliminated, these resources can otherwise be used as 
savings/investment or consumption, and are thus included (i.e., are added back in). 
Unfortunately, there is a relative paucity of comprehensive data on treatment costs, and even 
fewer sources that can be compared across countries. For example, in order to calibrate the model for TCt, 
we were obliged to adopt cost data on cancer from South Korea (20), COPD data from Europe (21), 
regional data on CVD (11), and diabetes data from Zhang et al. (22), as these were the only sources 
available. We were, however, able to locate country-specific estimates for CVD and diabetes in Peru from 
PAHO and for Jamaica from national accounts. This lack of data poses a significant hindrance to 
assessing the reliability of our estimates because it prevents comparison of cost information used in our 
study with other analyses. Collecting more treatment cost data is therefore an important item for future 
research. 
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Projecting counterfactual GDP  
The economic projection for the counterfactual scenario is implemented as follows: 
1) We use the status quo GDP projection to calculate physical capital in each year and then apply the 
Solow model to obtain the residual, At. We assume this total factor productivity remains the same in 
different scenarios. 
2) For the counterfactual, the GDP projection is calculated on a yearly basis using the projected labor 
supply, total factor productivity (At), and other economic parameters, such as the savings rate.  
The economic burden of a particular disease is then calculated as the difference in projected 
annual GDP between the status quo scenario and the counterfactual scenario in each year, summed over 
the period of interest. 
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APPENDIX B. Data sources 
TABLE A1. Data sources  
Inputs Data source 
Mortality WHO
a
, PAHO
b
, IHME
c 
Morbidity YLL
d
, YLD
e
 data are from WHO GHE
f
 2012 
Economic projection World Bank 
DALYs
g 
WHO GHE 2012 
Treatment cost (Costa Rica)  
Cancer Adjusted data from Kim et al. (20) 
CVD
h 
Regional treatment cost data from Bloom et al. (11) 
COPD
i 
BOLD
j
 study (21) 
Diabetes International Diabetes Federation Diabetes Atlas 2010 (22) 
Treatment cost (Peru)  
Cancer Adjusted data from Kim et al. (20) 
CVD PAHO 
COPD BOLD study (21) 
Diabetes PAHO 
Treatment cost (Jamaica) 
Final report of the development of NCD
k
 national health 
subaccounts (2012) 
Scaling factors Calculated using DALY data 
Population ILO
l 
Labor ILO 
𝜒m Assumed to be 10% for each country 
a 
WHO = World Health Organization. 
b
 PAHO = Pan American Health Organization. 
c 
IHME = Institute for Health Metrics and Evaluation. 
d 
YLL = years of life lost. 
e 
YLD = years of life lived with disability. 
f 
GHE = global health estimates. 
g 
DALY = disability-adjusted life years.
 
h 
CVD = cardiovascular disease. 
i 
COPD = chronic obstructive pulmonary disease. 
j 
BOLD = burden of obstructive lung disease. 
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k 
NCD = noncommunicable diseases. 
l 
ILO = International Labor Organization. 
m χ = the proportion of savings that goes towards either treatment or intervention costs. Note: following the WHO 
EPIC model, we assume χ is 10% (i.e.. 10% of treatment cost is diverted to savings when diseases are eliminated (in 
the counterfactual scenario)). 
 
APPENDIX C. Supplemental tables for key results 
TABLE A2. EPIC-H Plus output for Costa Rica 2015–2030a  
Disease 
Economic burden 
(billions of 2015 US$) 
Diabetes 4.88 
Cardiovascular disease 7.69 
Respiratory disease 16.44 
Cancer 6.48 
Mental health conditions 15.26 
Total NCDs and mental health conditions b 81.96 
a
 Estimates are from the baseline case, which uses WHO mortality data and assumes exponential 
mortality rate growth.  
b
 Total NCDs include cardiovascular diseases, cancer, chronic respiratory diseases, cirrhosis, digestive 
diseases, diabetes, urogenital diseases, blood diseases, endocrine diseases, and musculoskeletal disorders 
and other noncommunicable diseases, including congenital anomalies, skin and subcutaneous diseases, 
sense organ diseases, and oral disorders. 
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TABLE A3. EPIC-H Plus output for Jamaica 2015–2030a  
Disease 
Economic burden 
(billions of 2015 US$) 
Diabetes 2.48 
Cardiovascular disease 3.83 
Respiratory disease 1.03 
Cancer 2.52 
Mental health conditions 2.76 
Total NCDs and mental health conditions
b 
18.45 
a
 Estimates are from the baseline case, which uses WHO mortality data and assumes exponential mortality rate 
growth. 
b
 Total NCDs include cardiovascular diseases, cancer, chronic respiratory diseases, cirrhosis, digestive diseases, 
diabetes, urogenital diseases, blood diseases, endocrine diseases, and musculoskeletal disorders and other 
noncommunicable diseases, including congenital anomalies, skin and subcutaneous diseases, sense organ diseases, 
and oral disorders. 
TABLE A4. EPIC-H Plus output for Peru 2015–2030 a  
Disease 
Economic burden 
(billions of 2015 US$) 
Diabetes 19.81 
Cardiovascular disease 39.90 
Respiratory disease 93.81 
Cancer 30.78 
Mental health conditions 99.52 
Total NCDs and mental health conditions
b 
477.33 
a Estimates are from the baseline case, which uses WHO mortality data and assumes exponential mortality rate growth. 
b Total NCDs include cardiovascular diseases, cancer, chronic respiratory diseases, cirrhosis, digestive diseases, diabetes, 
urogenital diseases, blood diseases, endocrine diseases, and musculoskeletal disorders and other noncommunicable diseases, 
including congenital anomalies, skin and subcutaneous diseases, sense organ diseases, and oral disorders. 
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APPENDIX D. Sensitivity analysis 
For data on the mortality rate associated with each disease, we have three sources: the WHO, the 
Institute for Health Metrics and Evaluation (IHME), and PAHO.  
For each data source, we consider three cases for forecasting the mortality rate:  
1) the exponential case, which assumes the mortality rate growth trend is 
exponential and that the mortality rate in 2014–2030 follows the same growth rate as the 
mortality rate in 2005–2013 (note that our projection period for output loss is still from 
2015 to 2030, but here we need to do data processing starting from 2014)  
2) the constant case, which assumes the mortality rate in 2014–2030 is the same as 
that in 2013 
3) the linear case, which assumes the mortality rate growth trend is linear and that 
the mortality rate in 2014–2030 follows the same growth rate as the mortality rate in 
2005–2013  
We generate a set of four estimates for each case and for each data source:  
1) an estimate that includes the morbidity effect of NCDs and mental health 
conditions and where the treatment cost for NCDs and mental health conditions is 
nonzero  
2) an estimate with a morbidity effect but zero treatment cost 
3) an estimate with no morbidity effect and a nonzero treatment cost  
4) an estimate with neither a morbidity effect nor a treatment cost 
Therefore, there are 36 sensitivity analyses for each country. 
For the baseline scenario (discussed in the Results section), we use the WHO mortality data and 
assume an exponential mortality rate growth with a morbidity effect and a nonzero treatment cost. This 
choice is made for several reasons. First, the assumption that the mortality rate in 2014–2030 will follow 
the same growth rate as the mortality rate in 2005–2013 is more realistic than the assumption that the 
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mortality rate will remain at the 2013 level, since it is apparent from the data that the mortality rate has 
changed over time in the past. Second, treatment costs are, of course, nonzero in the real world. Finally, 
effective labor supply and thus output are both clearly affected by morbidity. 
 
The results are similar and robust across different projection methods and data sources 
Figures A1 through A6 compare total and per capita output losses due to NCDs and mental health 
conditions across different mortality rate forecasting assumptions: WHO data with the exponential 
mortality projection, WHO data with the constant mortality projection, and WHO data with the linear 
mortality projection. No substantial differences exist between cases that use different mortality 
projections.  
Figures A7 through A12 compare total and per capita output losses due to NCDs and mental 
health conditions across different mortality data sources: WHO data with the exponential mortality 
projection, IHME data with the exponential mortality projection, and PAHO data with the exponential 
mortality projection. The differences between cases using different data sources are small for Costa Rica 
and Jamaica. For Costa Rica, the output loss using IHME mortality data is slightly higher than that using 
PAHO mortality data and that using WHO mortality data. For Jamaica, the output loss using PAHO 
mortality data is the highest. Because WHO and IHME have a higher number of deaths than the PAHO 
data for the initial part of the study period but not throughout the period as a whole, the growth rate under 
an exponential mortality projection is likely to be higher when using PAHO mortality data than when 
using the WHO or IHME data. This might explain why PAHO data give higher output losses than the 
other two data sources. For Peru, the output loss using IHME mortality data is substantially higher than 
that obtained using PAHO and WHO mortality data. That is because IHME data differ more substantially 
from PAHO and WHO data for Peru than they do for the other countries. 
 
The impact of treatment cost and morbidity is quite substantial 
In the EPIC-H Plus model, we consider the impact of both treatment cost and morbidity in 
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addition to the impact of mortality, while EPIC considers only the impact of mortality. To illustrate the 
difference, we provide results for these cases:  
1) both treatment cost and morbidity effects are considered  
2) only the morbidity effect is considered  
3) only the treatment cost is considered  
4) neither treatment cost nor morbidity is considered 
Figures A13 through A15 provide comparisons among these four cases. The output loss 
differences between Case 1 and Case 4 are US$ 63 billion for Costa Rica, US$ 8 billion for Jamaica, and 
US$ 364 billion for Peru. These differences account for 76% of the total loss for Costa Rica, 45% for 
Jamaica, and 76% for Peru. This shows that treatment cost and morbidity substantially affect our 
estimates of the economic burden of NCDs and mental health conditions. Furthermore, we also conducted 
a decomposition, and, as Figures A16 and A17 indicate, we found that the total effect on output is larger 
when considering both morbidity and treatment costs than the sum of their separate effects. This is 
because the morbidity effect reduces the labor supply (𝐿𝑡) at the same time that treatment cost reduces the 
stock of physical capital (𝐾𝑡). From equation (1) we can see that these two effects are not additive, 
because output is a function of the product of 𝐿𝑡
1−𝛼 and 𝐾𝑡
𝛼. This nonlinearity gives rise to the interaction 
effect that makes the combination of the two effects larger than their simple sum. We can also conclude 
that the effect of including morbidity in the model is greater than the effect of including treatment cost for 
Jamaica and Peru, while the reverse is true for Costa Rica. 
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FIGURE A1. Estimates of lost gross domestic product (GDP) output due to four leading 
noncommunicable diseases (NCDs), mental health conditions, and all NCDs and mental health 
conditions across different mortality rate assumptions in Costa Rica, 2015–2030 
 
Source: Prepared by the authors based on the results of the study. 
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FIGURE A2. Estimates of lost gross domestic product (GDP) output per capita due to four leading 
noncommunicable diseases (NCDs), mental health conditions, and all NCDs and mental health 
conditions across different mortality rate assumptions in Costa Rica, 2015–2030  
 
 
 
Source: Prepared by the authors based on the results of the study. 
 
 
 
 
 
 
961 1 027 920
1 514 1 651 1 473
3 238 3 331 3 171
1 275 1 308 1 265
3 005 3 146 2 937
16 143
16 901
15 776
0
5
 0
0
0
1
5
 0
0
0
2
0
 0
0
0
1
0
 0
0
0
2
0
1
5
 U
S
$
 
Diabetes Cardiovascular
disease
Respiratory
disease
Cancer Mental health
conditions
All NCDs
and mental health
conditions
Exponential (WHO) Constant (WHO) Linear (WHO)
13 
 
FIGURE A3. Estimates of lost gross domestic product (GDP) output due to four leading 
noncommunicable diseases (NCDs), mental health conditions, and all NCDs and mental health 
conditions across different mortality rate assumptions in Jamaica, 2015–2030  
 
 
 
 
 
 
Source: Prepared by the authors based on the results of the study. 
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FIGURE A4. Estimates of lost gross domestic product (GDP) output per capita due to four leading 
noncommunicable diseases (NCDs), mental health conditions, and all NCDs and mental health 
conditions across different mortality rate assumptions in Jamaica, 2015–2030  
 
 
 
Source: Prepared by the authors based on the results of the study. 
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FIGURE A5. Estimates of lost gross domestic product (GDP) output due to four leading 
noncommunicable diseases (NCDs), mental health conditions, and all NCDs and mental health 
conditions across different mortality rate assumptions in Peru, 2015–2030  
  
Source: Prepared by the authors based on the results of the study. 
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FIGURE A6. Estimates of lost gross domestic product (GDP) output per capita due to four leading 
noncommunicable diseases (NCDs), mental health conditions, and all NCDs and mental health 
conditions across different mortality rate assumptions in Peru, 2015–2030  
  
Source: Prepared by the authors based on the results of the study. 
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FIGURE A7. Estimates of lost gross domestic product (GDP) output due to four leading 
noncommunicable diseases (NCDs), mental health conditions, and all NCDs and mental health 
conditions across different mortality rate data sources in Costa Rica, 2015–2030  
  
Source: Prepared by the authors based on the results of the study. 
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FIGURE A8. Estimates of lost gross domestic product (GDP) output per capita due to four leading 
noncommunicable diseases (NCDs), mental health conditions, and all NCDs and mental health 
conditions across different mortality rate data sources in Costa Rica, 2015–2030 
  
Source: Prepared by the authors based on the results of the study. 
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FIGURE A9. Estimates of lost gross domestic product (GDP) output due to four leading 
noncommunicable diseases (NCDs), mental health conditions, and all NCDs and mental health 
conditions across different mortality rate data sources in Jamaica, 2015–2030 
  
Source: Prepared by the authors based on the results of the study. 
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FIGURE A10. Estimates of lost gross domestic product (GDP) output per capita due to four leading 
noncommunicable diseases (NCDs), mental health conditions, and all NCDs and mental health 
conditions across different mortality rate data sources in Jamaica, 2015–2030  
  
Source: Prepared by the authors based on the results of the study. 
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FIGURE A11. Estimates of lost gross domestic product (GDP) output due to four leading 
noncommunicable diseases (NCDs), mental health conditions, and all NCDs and mental health 
conditions across different mortality rate data sources in Peru, 2015–2030  
  
Source: Prepared by the authors based on the results of the study. 
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FIGURE A12. Estimates of lost gross domestic product (GDP) output per capita due to four leading 
noncommunicable diseases (NCDs), mental health conditions, and all NCDs and mental health 
conditions across different mortality rate data sources in Peru, 2015–2030 
 
Source: Prepared by the authors based on the results of the study. 
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FIGURE A13. Estimates of lost gross domestic product (GDP) output due to four leading 
noncommunicable diseases (NCDs), mental health conditions, and all NCDs and mental health 
conditions across different cases in Costa Rica, 2015–2030  
  
Source: Prepared by the authors based on the results of the study. 
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FIGURE A14. Estimates of lost gross domestic product (GDP) output due to four leading 
noncommunicable diseases (NCDs), mental health conditions, and all NCDs and mental health 
conditions across different cases in Jamaica, 2015–2030  
 
Source: Prepared by the authors based on the results of the study. 
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FIGURE A15. Estimates of lost gross domestic product (GDP) output due to four leading 
noncommunicable diseases (NCDs), mental health conditions, and all NCDs and mental health 
conditions across different cases in Peru, 2015–2030  
  
Source: Prepared by the authors based on the results of the study. 
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FIGURE A16. Decomposition of lost gross domestic product (GDP) output due to all NCDs and 
mental health conditions for three countries caused by various effects in absolute value, 2015–2030  
  
Source: Prepared by the authors based on the results of the study. 
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FIGURE A17. Decomposition of lost gross domestic product (GDP) output due to all NCDs and 
mental health conditions for three countries caused by various effects as a percentage of total 
burden of disease, 2015–2030 
  
Source: Prepared by the authors based on the results of the study. 
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